Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11780839 Compounds for treating Huntington's disease

Patent 11780839 was granted and assigned to PTC Therapeutics, Inc. on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

PTC Therapeutics, Inc.

Current Assignee

PTC Therapeutics, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Jigar S. Patel

Nicholas W. Mszar

Nadiya Sydorenko

Lukiana Amedzo

Nanjing Zhang

Anthony R. Mazzotti

Anuradha Bhattacharyya

Suresh Babu

...

Date of Patent

October 10, 2023

Patent Application Number

17040104

Date Filed

March 27, 2019

Patent Citations

US Patent 7897792 Coumarin derivative having antitumor activity

US Patent 7910578 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use

US Patent 8143274 1-(2H)-isoquinolone derivative

US Patent 8314119 Azaadamantane derivatives and methods of use

US Patent 8337941 Fluorescent substrates for monoamine transporters as optical false neurotransmitters

US Patent 8563550 Imidazolothiadiazoles for use as protein kinase inhibitors

US Patent 8633019 Methods for treating spinal muscular atrophy

US Patent 8846661 Diazahomoadamantane derivatives and methods of use thereof

...

Patent Primary Examiner

Laura L. Stockton

CPC Code

...

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11780839 Compounds for treating Huntington's disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.